Suramin . hexasodium salt [129-46-4]
AG-CR1-3575
CAS Number129-46-4
Product group Chemicals
Estimated Purity>98%
Molecular Weight1291.2 . 137.9
Overview
- SupplierAdipoGen Life Sciences
- Product NameSuramin . hexasodium salt
- Delivery Days Customer10
- CAS Number129-46-4
- CertificationResearch Use Only
- Estimated Purity>98%
- Molecular FormulaC51H34N6O23S6 . 6Na
- Molecular Weight1291.2 . 137.9
- Scientific DescriptionChemical. CAS: 129-46-4. Formula: C51H34N6O23S6 . 6Na. MW: 1291.2 . 137.9. Synthetic. Potent ATPase inhibitor. Potent competitive inhibitor of reverse transcriptase. Shows anti-HIV activity. Anticancer compound. Protein kinase C (PKC) inhibitor. Potent inhibitor of melanoma heparanase and tumor cell metastasis. Non-specific growth factors inhibitor (including PDGF, EGF, aFGF and bFGF). TGF-beta1 inhibitor. Topoisomerase I and II inhibitor. Interleukin-1 (IL-1) inhibitor. Interleukin-4 (IL-4) inhibitor. G protein inhibitor. P2X and P2Y purinergic receptor antagonist. Antiangiogenic. Potent VEGF inhibitor. Telomerase inhibitor. Shows adjuvant properties. Regulates ryanodine receptor. Direct adenylyl cyclase inhibitor. Protein synthesis inhibitor. SIRT1 (sirtuin 1) and SIRT5 (sirtuin 5) inhibitor. Immunosuppressive. Antifibrotic agent. Antiparasitic. Antiprotozoal. Athelmintic. Cullin-RING E3 ubiquitin ligase inhibitor. - Potent ATPase inhibitor [1]. Potent competitive inhibitor of reverse transcriptase. Shows anti-HIV activity [2, 3]. Anticancer compound [4, 5, 15]. Protein kinase C (PKC) inhibitor [4]. Potent inhibitor of melanoma heparanase and tumor cell metastasis [6]. Non-specific growth factors inhibitor (including PDGF, EGF, aFGF and bFGF) [7, 16]. TGF-beta1 inhibitor [8]. Topoisomerase I and II inhibitor [9]. Interleukin-1 (IL-1) inhibitor [10]. Interleukin-4 (IL-4) inhibitor [11]. G protein inhibitor [12]. P2X and P2Y purinergic receptor antagonist [13]. Antiangiogenic. Potent VEGF inhibitor [14, 15]. Telomerase inhibitor [17]. Shows adjuvant properties [18]. Regulates ryanodine receptor [19]. Direct adenylyl cyclase inhibitor [20]. Protein synthesis inhibitor [21]. SIRT1 (sirtuin 1) and SIRT5 (sirtuin 5) inhibitor [22, 23]. Immunosuppressive [24]. Antifibrotic agent [25]. Antiparasitic. Antiprotozoal. Athelmintic [26]. Cullin-RING E3 ubiquitin ligase inhibitor [27]. Inhibitor of the STING pathway via the inhibition of cGAMP synthase (cGAS) enzymatic activity. Inhibits SARS-CoV-2 infection in cell culture by blocking early steps (binding/fusion) of the replication cycle. Potentially binds and inhibits nsp12 of SARS-CoV-2, binding to motifs harbouring the RNA-dependent RNA polymerases (RdRps) activity.
- SMILES[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].CC1=CC=C(C=C1NC(=O)C1=CC(NC(=O)NC2=CC=CC(=C2)C(=O)NC2=C(C)C=CC(=C2)C(=O)NC2=C3C(C=C(C=C3S([O-])(=O)=O)S([O-])(=O)=O)=C(C=C2)S([O-])(=O)=O)=CC=C1)C(=O)NC1=CC=C(C2=C1C(=CC(=C2)S([O-])(=O)=O)S([O-])(=O)=O)S([O-])(=O)=O
- Storage Instruction2°C to 8°C
- UNSPSC12352200
References
- Suramin: a potent ATPase inhibitor which acts on the inside surface of the sodium pump: P.A. Fortes, et al.; Biochim. Biophys. Acta 318, 262 (1973)
- Suramin: a potent inhibitor of the reverse transcriptase of RNA tumor viruses: E. De Clerq; Cancer Lett. 8, 9 (1979)
- Suramin protection of T cells in vitro against infectivity and cytopathic effect of HTLV-III: H. Mitsuya, et al.; Science 226, 172 (1984)
- Suramin, an anti-cancer drug, inhibits protein kinase C and induces differentiation in neuroblastoma cell clone NB2A: C.E. Hensey, et al.; FEBS Lett. 258, 156 (1989)
- Suramin: prototype of a new generation of antitumor compounds: R.V. La Rocca, et al.; Cancer Cells 2, 106 (1990) (Review)
- Suramin. A potent inhibitor of melanoma heparanase and invasion: M. Nakajima, et al.; J. Biol. Chem. 266, 9661 (1991)
- Nature of the interaction of growth factors with suramin: C.R. Middaugh, et al.; Biochemistry 31, 9016 (1992)
- The antiproliferative effect of suramin on the cancer cell line SW-13 is mediated by the inhibition of transforming growth factor beta 1 (TGF-beta 1): R. Danesi, et al.; Pharmacol. Res. 25, 17 (1992)
- Suramin inhibits DNA damage in human prostate cancer cells treated with topoisomerase inhibitors in vitro: H. Yamazaki, et al.; Prostate 23, 25 (1993)
- Suramin blocks the binding of interleukin-1 to its receptor and neutralizes IL-1 biological activities: G. Strassmann, et al.; Int. J. Immunopharmacol. 16, 931 (1994)